NCT01263808View on ClinicalTrials.gov

Cardiac Safety of Indacaterol

PHASE1CompletedINTERVENTIONAL
Enrollment

404

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2008

Conditions
Healthy VolunteersChronic Obstructive Pulmonary Disease
Interventions
DRUG

Indacaterol 150 µg

Once daily (QD) via single-dose dry powder inhaler (SDDPI)

DRUG

Indacaterol 300 µg

QD via SDDPI

DRUG

Indacaterol 600 µg

QD via SDDPI

DRUG

Placebo

QD via SDDPI

DRUG

Placebo/moxifloxacin

Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg

Trial Locations (1)

33126

Novartis investigative site, Miami

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY